Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Any KLY news from an independent source?

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Sep 10, 2020 10:21am

173 Views

Post# 31532724

RE:RE:RE:RE:RE:RE:RE:RE:RE:Any KLY news from an independent source?

I, like most of the other "bashers" here, was scamned by the GVHD research. We "acquired" Talent, which had basically 1 promising asset, publicly funded the research, then handed it back consequence free but with KLY massively diluted and our share price annihilated.

Sound familiar?

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks